ImPact Biotech

Targeted Treatment for Selective Tumor Ablation

Health Tech & Life Sciences
Active
Pre-Funding Ness Ziona, Israel Founded 1996
Website ↗ LinkedIn
Last updated 2026-06-18
Total raised
$2.7M
Last: Grant 2024-07
Stage
Pre-Funding
Founded
1996
Headcount
40
HQ
Ness Ziona, Israel
Sector
Health Tech & Life Sciences

About

ImPact Biotech is focused on the development and launch of Padeliporfin Vascular Targeted Photodynamic (VTP) therapy, a targeted treatment for selective tumor ablation. Padeliporfin VTP therapy is a novel Oncology technology platform that comprises the intravenous delivery of an inactive drug, Padeliporfin, which is then precisely activated only in the tumor micro-environment by non-thermal laser light delivered via optical fiber(s). This results in the immediate occlusion of the tumor blood supply followed by self-propagating immunogenic cell death and immune activation with minimal effect on surrounding healthy tissues.

ImPact Biotech holds exclusive rights from the Weizmann Institute of Science (WIS, Israel) and Memorial Sloan Kettering Cancer Center (MSKCC, New York), to develop and commercialize drugs and related technologies used in VTP.

Funding history · 1 round · $2.7M total

2024-07

Q&A

What is ImPact Biotech's primary focus?
ImPact Biotech focuses on developing and launching Padeliporfin Vascular Targeted Photodynamic (VTP) therapy, a targeted treatment for selective tumor ablation.
When was ImPact Biotech founded?
ImPact Biotech was founded in January 1996.
How many employees does ImPact Biotech have?
ImPact Biotech has 11-50 employees.
What is the total amount of funding ImPact Biotech has raised?
ImPact Biotech has raised a total of $2,700,000.
When was ImPact Biotech's most recent funding round and who participated?
ImPact Biotech secured a Grant round in July 2024, with the European Innovation Council participating.
What technology platform does ImPact Biotech utilize for its therapy?
ImPact Biotech utilizes an Oncology technology platform where an inactive drug, Padeliporfin, is intravenously delivered and then activated precisely in the tumor micro-environment by non-thermal laser light.
From which institutions does ImPact Biotech hold exclusive rights for its VTP technology?
ImPact Biotech holds exclusive rights from the Weizmann Institute of Science (WIS, Israel) and Memorial Sloan Kettering Cancer Center (MSKCC, New York) for the development and commercialization of VTP drugs and related technologies.
Who is the CEO of ImPact Biotech?
Barak Palatchi is the CEO of ImPact Biotech.

Sectors & technology

Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
BiologicalsCells
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business model
B2B

Highlights

1 Patents

Tags

biotechnologyoncologycancer-therapypharmaceuticalsimmunotherapycancerminimally-invasive
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)